As early as 2007, Kneifel and collaborators demonstrated the feasibility of a protocol for radionuclide therapy with 90Y-DOTAGA-substance P in patients with malignant gliomas (in this study were included four patients with glioblastomas, two with anaplastic gliomas and six with low-grade gliomas). Here, TAC1 is linked to glioblastoma.